Formation Bio Lands $372M Series D Amid AI-Driven Expansion
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
- Latest
- Trending
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
The department's new drone fleet, patrolling bays, beaches, and boardwalks, proves effective; hopes to train more officers as certified pilots.
Swiss chemist Albert Hofmann first synthesized LSD in the 1930s. While research eventually halted, the drug is now being decriminalized ...
Many investors favor stocks that provide passive income. Notable choices include Realty Income, Home Depot, and Starbucks, known for high ...
Billionaires Warren Buffett and Ken Griffin own Vanguard's S&P 500 ETF. Despite contradictory strategies, investing in this popular ETF has ...
JPMorgan analyst Ryan Brinkman rates Tesla stock a sell, valuing it at $115 per share due to high forward earnings ...
Meta has released a new version of its Llama AI model to compete with OpenAI, X, and Google. Despite ongoing ...
Fund managers often struggle to outperform the S&P 500 due to two major factors. Even Berkshire Hathaway holds positions in ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.